Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind study. by Odutola, Aderonke et al.
Odutola, A; Ota, MO; Antonio, M; Ogundare, EO; Saidu, Y; Foster-
Nyarko, E; Owiafe, PK; Ceesay, F; Worwui, A; Idoko, OT; Owolabi,
O; Bojang, A; Jarju, S; Drammeh, I; Kampmann, B; Greenwood,
BM; Alderson, M; Traskine, M; Devos, N; Schoonbroodt, S; Swinnen,
K; Verlant, V; Dobbelaere, K; Borys, D (2017) Efficacy of a novel,
protein-based pneumococcal vaccine against nasopharyngeal carriage
of Streptococcus pneumoniae in infants: A phase 2, randomized, con-
trolled, observer-blind study. Vaccine, 35 (19). pp. 2531-2542. ISSN
0264-410X DOI: https://doi.org/10.1016/j.vaccine.2017.03.071
Downloaded from: http://researchonline.lshtm.ac.uk/4002745/
DOI: 10.1016/j.vaccine.2017.03.071
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
Efficacy of a novel, protein-based pneumococcal vaccine against
nasopharyngeal carriage of Streptococcus pneumoniae in infants:
A phase 2, randomized, controlled, observer-blind study
Aderonke Odutola a,⇑, Martin O.C. Ota a, Martin Antonio a, Ezra O. Ogundare a, Yauba Saidu a,
Ebenezer Foster-Nyarko a, Patrick K. Owiafe a, Fatima Ceesay a, Archibald Worwui a, Olubukola T. Idoko a,
Olumuyiwa Owolabi a, Abdoulie Bojang a, Sheikh Jarju a, Isatou Drammeh a, Beate Kampmann a,
Brian M. Greenwood b, Mark Alderson c, Magali Traskine d, Nathalie Devos d, Sonia Schoonbroodt d,
Kristien Swinnen d, Vincent Verlant d, Kurt Dobbelaere d, Dorota Borys d
aMedical Research Council Unit, Vaccines & Immunity Theme, Banjul, Gambia
b Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK
cPATH, Seattle, WA, USA
dGSK, Wavre, Belgium
a r t i c l e i n f o
Article history:
Received 7 December 2016
Received in revised form 21 March 2017
Accepted 22 March 2017
Available online 4 April 2017
Keywords:
Streptococcus pneumoniae
Nasopharyngeal carriage
Pneumolysin
Pneumococcal histidine triad protein D
Vaccine efficacy
Infant
a b s t r a c t
Background: Conserved pneumococcal proteins are potential candidates for inclusion in vaccines against
pneumococcal diseases. In the first part of a two-part study, an investigational vaccine (PHiD-CV/dPly/
PhtD-30) containing 10 pneumococcal serotype-specific polysaccharide conjugates (10VT) combined
with pneumolysin toxoid and pneumococcal histidine triad protein D (30 lg each) was well tolerated
by Gambian children. Part two, presented here, assessed the efficacy of two PHiD-CV/dPly/PhtD formu-
lations against pneumococcal nasopharyngeal carriage (NPC) prevalence in infants.
Methods: In this phase 2, randomized, controlled, observer-blind trial, healthy infants aged 8–10 weeks,
recruited from a peri-urban health center, were randomized (1:1:1:1:1:1) into six groups. Four groups
received PHiD-CV/dPly/PhtD (10 or 30 lg of each protein), PHiD-CV, or 13-valent pneumococcal conju-
gate vaccine at ages 2–3–4 months (3 + 0 infant schedule) and two groups PHiD-CV/dPly/PhtD-30 or
PHiD-CV at 2–4–9 months (2 + 1 infant schedule). The primary objective was impact on non-10VT NPC
at ages 5–9–12 months. Secondary objectives included confirmatory analysis of protein dose superiority
and safety/reactogenicity. Impact on pneumococcal NPC acquisition, bacterial load, and ply and phtD gene
sequencing were explored.
Results: 1200 infants were enrolled between June 2011 and May 2012. Prevalences of pneumococcal (60–
67%) and non-10VT (55–61%) NPC were high at baseline. Across all post-vaccination time points, efficacy
of PHiD-CV/dPly/PhtD-10 and PHiD-CV/dPly/PhtD-30 against non-10VT NPC (3 + 0 schedule) was 1.1%
(95% CI 21.5, 19.5) and 2.1% (20.3, 20.3), respectively; efficacy of PHiD-CV/dPly/PhtD-30 (2 + 1 sched-
ule) was 0.5% (22.1, 18.9) versus PHiD-CV. No differences were observed in pneumococcal NPC acqui-
sition, clearance, or bacterial load. Both protein-based vaccines elicited immune responses to
pneumococcal proteins.
http://dx.doi.org/10.1016/j.vaccine.2017.03.071
0264-410X/ 2017 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Expanded Program on Immunization; GMC, geometric mean concentration; IPD, invasive pneumococcal disease; non-10VT, non-PHiD-CV pneumococcal serotypes or
serogroups; NPC, nasopharyngeal carriage; PCV, pneumococcal conjugate vaccine; PHiD-CV, pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine;
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Conclusions: In this high carriage prevalence setting, inclusion of pneumococcal proteins in the PHiD-CV/
dPly/PhtD investigational vaccine had no impact on pneumococcal NPC in infants, regardless of protein
dose or schedule. Future evaluations will assess its impact against pneumococcal disease endpoints.
Funding: PATH, GlaxoSmithKline Biologicals SA. ClinicalTrials.gov identifier NCT01262872.
 2017 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
Remarkable reductions in the incidence of vaccine serotype
invasive pneumococcal disease (IPD) and nasopharyngeal carriage
(NPC) prevalence have been recorded in countries that have
included a pneumococcal conjugate vaccine (PCV) in their infant
immunization program [1–3]. This was observed in The Gambia
following the introduction of the seven-valent PCV (PCV7) into
its immunization program in August 2009 followed by replace-
ment with the 13-valent vaccine (PCV13) in May 2011 [4,5].
Immunization with PCVs also has indirect effects, leading to
decreases in the incidence of vaccine serotype carriage and disease
in non-vaccinated populations [6]. However, use of PCVs is limited
by the potential for serotype replacement and high manufacturing
costs [3,7]. Protein antigens that are conserved across all pneumo-
coccal serotypes have therefore been explored as an alternative
and a number, used either alone or in combination with other pro-
teins or polysaccharide conjugates, are being evaluated in clinical
trials after demonstration of protection against pneumococcal dis-
ease or carriage in animal models [3,8–14].
Two protein candidates, pneumolysin (Ply) [15] and pneumo-
coccal histidine triad protein D (PhtD) [16] (alone or in combina-
tion), have shown protection against lethal challenge, septicemia,
pneumonia, and NPC prevalence in animal models [17–23] and
have been selected for clinical development by GSK (Belgium).
Investigational vaccines containing dPly (a pneumolysin toxoid)
and PhtD (two formulations with either 10 or 30 lg of each pro-
tein) plus 10 serotype-specific polysaccharide conjugates of the
pneumococcal non-typeable Haemophilus influenzae protein D con-
jugate vaccine (PHiD-CV/dPly/PhtD-10 or PHiD-CV/dPly/PhtD-30)
were well tolerated and immunogenic in healthy European adults
[11] and toddlers [12]. The PHiD-CV/dPly/PhtD-30 formulation was
also well tolerated and immunogenic in children aged 2–4 years in
the first part of this study conducted in The Gambia [13]. In the
second part, we evaluated the impact of the two protein-based
pneumococcal vaccine formulations on NPC prevalence of pneu-
mococci, and their reactogenicity, safety, and immunogenicity in
infants when given in a three-dose schedule together with routine
Expanded Program on Immunization (EPI) vaccines.
2. Methods
2.1. Study design and participants
A phase 2 randomized, controlled, observer-blind study was
conducted at the Fajikunda Health Center situated in a peri-
urban area of The Gambia. The prevalence of pneumococcal NPC
in infants in Fajikunda was known to be high (76% in children aged
15–53 weeks) [24]. The study area and population have been
described previously [24]. The study was conducted in accordance
with Good Clinical Practice guidelines and principles of the Decla-
ration of Helsinki. Written informed consent was obtained from a
parent or legally-acceptable representative of each infant before
any study procedure was performed except when deviations from
the informed consent process occurred (Supplementary Text 1).
Interest in participating in the trial was determined from
mothers at the time of delivery in the health center or when
the infant was brought for first immunizations shortly after birth.
Healthy infants aged 8–10 weeks were recruited at the health
center when brought for immunizations scheduled at two months
of age. Inclusion and exclusion criteria are listed in Supplemen-
tary Text 2.
Eligible participants were randomized (1:1:1:1:1:1) into one of
six groups using a computer-generated, block randomization pro-
gram (block size of six). The methods for pneumococcal vaccine
allocation and blinding are described in Supplementary Text 2.
Infants in four groups were vaccinated at 2, 3, and 4 months of
age with PHiD-CV/dPly/PhtD-30, PHiD-CV/dPly/PhtD-10, PHiD-CV
(Synflorix; GSK, Belgium), or PCV13 (Prevenar 13; Pfizer, USA) (3
+ 0 infant schedule) (Fig. 1). Infants in the remaining two groups
received either PHiD-CV/dPly/PhtD-30 or PHiD-CV at 2, 4, and
9 months of age (2 + 1 infant schedule).
Administration of other vaccines (Supplementary Text 2) was in
accordance with the routine Gambian EPI schedule.
2.2. Study endpoints
The primary trial endpoint was the detection of non-10VT
serotypes/groups in the nasopharynx at post-immunization visits
at ages 5, 9, and 12 months, which was one, five, and eight months
after the third vaccine dose in the 3 + 0 groups, and one and five
months after the second dose and three months after the booster
dose in the 2 + 1 groups. Non-10VT serotypes/groups included
any pneumococcal isolates with unknown or determined serotype
or serogroup other than those included in the 10-valent PHiD-CV
(serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F). The first sec-
ondary endpoint was the immune response to Ply and PhtD given
at a dose of 10 or 30 lg. A list of primary and secondary endpoints
is provided in Supplementary Text 2.
2.3. Study vaccines
The investigational pneumococcal vaccines (PHiD-CV/dPly/
PhtD-10 or PHiD-CV/dPly/PhtD-30) contained dPly and PhtD at
10 or 30 lg each, combined with the 10 serotype-specific PHiD-
CV polysaccharide conjugates, as described previously [13]. The
antigens were adsorbed on aluminum phosphate (vaccine adju-
vant; aluminum content 500 lg). The control vaccines were
PHiD-CV and PCV13. All pneumococcal vaccines were provided
by GSK as mono-dose vials (PHiD-CV and PHiD-CV/dPly/PhtD vac-
cines) or pre-filled syringes (PCV13) and administered intramuscu-
larly into the right thigh. All other co-administered injectable
vaccines were administered intramuscularly into the left thigh.
2.4. Study procedures
Nasopharyngeal swabs were obtained (as described previously
[24], apart from the use of flocked nylon-tipped swabs in this
study) from all participants at recruitment (age 8–10 weeks), and
at ages 5, 9, and 12 months. A study-specific microbiological labo-
ratory standard operating procedure was followed at the Medical
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Research Council (The Gambia) laboratory for identification of S.
pneumoniae, H. influenzae, Staphylococcus aureus, Moraxella catar-
rhalis, and Group A Streptococcus by standard microbiological cul-
ture and biochemical tests, and serotyping of S. pneumoniae
isolates. Results for bacteria other than S. pneumoniae will be pre-
sented elsewhere. The adapted broth enrichment method for S.
pneumoniae identification, latex agglutination method for serotyp-
ing of S. pneumoniae isolates, and bacterial load measurement by
quantitative polymerase chain reaction (qPCR) testing and by cul-
ture semi-quantitative counts are described in Supplementary Text
2. Because of technical limitations with the latex agglutination
method, results were presented at the serogroup level, except
when vaccine or vaccine-related serotypes were determined. Ser-
ogroup 6 and serotypes 9A/9V underwent final serotyping by Quel-
lung reaction at Q2 Solutions (USA). The phtD and ply gene
sequencing method for a subset of nasopharyngeal swab isolates
containing non-10VT serotypes/serogroups is described in Supple-
mentary Text 2.
Blood samples for immunogenicity assessments were taken
before vaccination and at ages 5, 9, and 12 months. Antibodies
against Ply and PhtD were quantified using GSK in-house individ-
ual enzyme-linked immunosorbent assays (ELISAs), with technical
cut-off of 12 and 17 ELISA units per mL, respectively. Results of
other immunogenicity assessments will be described elsewhere.
The reactogenicity and safety assessments are described in Sup-
plementary Text 2.
2.5. Statistical analysis
A sample size of 200 participants per group allowed detection of
35% reduction in non-10VT carriage prevalence with 82% power,
assuming that non-10VT carriage prevalence in the comparator
PHiD-CV group was 40%. Vaccine efficacy against NPC prevalence
was estimated as 1 minus the relative risk at all post-vaccination
time points in the total vaccinated cohort, which included all vac-
cinated infants. The assessment of vaccine efficacy against NPC
prevalence was descriptive, with no pre-defined criteria.
Percentages of infants with nasopharyngeal swabs positive for
S. pneumoniae were calculated with non-adjusted 95% confidence
intervals (CIs) at each collection time point, as well as the fre-
quency of acquisition or clearance of serotypes/groups. Acquisition
at a particular visit was determined when a nasopharyngeal swab
was positive for a specific serotype/group after a negative sample
for the same infant at the previous visit. Clearance was determined
when a swab was negative for a specific serotype/group after a
positive swab at the previous visit. Per episode analyses were con-
ducted for acquisition and clearance, in which each new or cleared
serotype/group at a visit was counted as a separate episode, allow-
ing for the carriage of multiple serotypes/groups in an individual.
The first secondary (confirmatory) objective was to compare the
immunogenicity of protein doses (10 or 30 lg) given in the 3 + 0
schedule. Superiority of one formulation over the other was to be
demonstrated if the 95% CIs for the antibody geometric mean con-
centration (GMC) ratios (analysis of covariance model with adjust-
ment for baseline concentrations; pooled variance) between the
30 lg group and 10 lg group did not include 1 for antibody
responses against both Ply and PhtD.
qPCR was performed on swabs from 50% of enrolled subjects
(100 infants per group; total vaccinated cohort for qPCR analysis).
Immunogenicity analyses were performed on the according-to-
protocol cohort for immunogenicity, defined as vaccinated infants
who met all eligibility criteria, complied with all study procedures,
and for whom immunogenicity data were available. Safety analy-
ses were done on the total vaccinated cohort. Exploratory analyses
BS 
NS 
BS 
NS 
BS 
NS 
BS 
NS 
Adverse event (AE) 
reporting 
Solicited AE reporting (day 0–day 3)  
Unsolicited AE reporting (day 0–day 30)  
SAE reporting  
PHiD-CV/dPly/PhtD-10 
PHiD-CV/dPly/PhtD-30 
PHiD-CV 
PCV13 
3+0 schedule given at ages 2, 3, 4 months 
12 95432Age (months) 
AE 
reporting 
Solicited AE reporting (day 0–day 3)  
Unsolicited AE reporting (day 0–day 30)  
SAE reporting 
PHiD-CV/dPly/PhtD-30 
PHiD-CV 
2+1 schedule given at ages 2, 4, 9 months 
12 95432Age (months) 
8–10 week old infants  
Randomisation 1:1:1:1:1:1 
BS 
NS 
BS 
NS 
BS 
NS 
BS 
NS 
Fig. 1. Study design. BS, blood sample; NS, nasopharyngeal swab sample; SAE, serious adverse event; , vaccine administration. Diphtheria-tetanus-whole cell pertussis-
hepatitis B/Haemophilus influenzae type b and oral polio vaccines were administered at ages 2, 3, and 4 months; yellow fever, measles, and oral polio vaccines were
administered at age 9 months.
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were conducted in infants with or without pneumococcal NPC at
first study visit and in infants grouped according to timing of first
study vaccination: August to October 2011, November 2011 to
February 2012, and March to May 2012 and July 2011 (rainy sea-
son: June to October). In all exploratory analyses, 95% CIs were
used to highlight potential group differences. Since there was no
adjustment for multiplicity, such differences were to be inter-
preted with caution.
The statistical analyses were performed using SAS Drug and
Development web portal version 4.3.2 and SAS version 9.3 (SAS
Institute, USA).
3. Results
3.1. Demographics
Of 1200 infants enrolled between June 2011 and May 2012,
1152 (96%) completed the study. Participant flow is shown in
Fig. 2. The last study visit took place on 18 March 2013. Baseline
characteristics were similar across the groups (Supplementary
Table S1).
3.2. Serotype/group NPC prevalence and vaccine efficacy
A nasopharyngeal swab sample was cultured for all infants at
the first study visit and for at least 99.0% of infants who attended
subsequent study visits in each group. The most frequent pneumo-
coccal serotypes/groups identified in the nasopharyngeal swab
samples across all time points were 15 (22.0–32.5%), 19A (20.5–
31.5%), and 35 (21.5–28.0%) (Supplementary Table S2). Among
PHiD-CV serotypes, serotype 19F (10.5–18.0%) followed by 23F
(5.0–11.0%) had the highest incidence, while the most common
vaccine-related serotypes were 6A (13.0–22.5%) and 19A (20.5–
31.5%).
In this study setting, there were no differences in prevalence of
non-10VT NPC between groups receiving the pneumococcal
protein-based vaccine compared to PHiD-CV control groups,
regardless of dose (10 or 30 lg) or schedule (3 + 0 or 2 + 1)
(Table 1). The carriage prevalence of non-10VT, any pneumococci,
or PHiD-CV serotypes was in the same range among groups at each
post-vaccination visit (Table 1). Similarly, assessment of the num-
bers of serotypes/groups acquired or cleared at the next visit did
not show differences between PHiD-CV/dPly/PhtD and PHiD-CV
groups for any serotype/group category (Tables 2 and 3). Acquisi-
tion of non-10VT carriage was more frequent than their clearance
(Tables 2 and 3), leading to an increase in non-10VT NPC preva-
lence after primary vaccination (Table 1). No differences were
observed across groups in pneumococcal load as measured by
qPCR (Fig. 3) or semi-quantitative culture assessment (Supplemen-
tary Table S3) at any post-vaccination time point.
Exploratory analyses of infants with or without pneumococcal
NPC before vaccination did not suggest any differences in preva-
lence, acquisition, or clearance of non-10VT or any pneumococci
between the groups who received the pneumococcal protein-
based vaccine and PHiD-CV groups (Supplementary Tables S4
and S5). Timing of first vaccination according to season also did
not alter the vaccine’s effect on carriage prevalence of non-10VT
or any pneumococci following vaccination, although seasonal
trends were observed (Supplementary Table S6, Fig. S1).
3.3. Immunogenicity
Before vaccination, all infants in all groups had detectable anti-
body concentrations against Ply and PhtD (above the cut-off val-
ues). There was a 10- to 18-fold increase in antibody
1200 enrolled* 
1200 randomised and included 
in total vaccinated cohort 
4 excluded 
4 essential serological data 
missing 
5 discontinued treatment 
3 withdrew consent 
2 moved away 
200 assigned  
PHiD-CV 3+0 
195 included in ATP 
immunogenicity 
analysis 
196 included in ATP 
immunogenicity 
analysis 
192 included in ATP 
immunogenicity 
analysis 
193 included in ATP 
immunogenicity 
analysis 
193 included in ATP 
immunogenicity 
analysis 
195 included in ATP 
immunogenicity 
analysis 
9 discontinued treatment 
1 protocol violation 
4 withdrew consent 
4 moved away 
200 assigned  
PHiD-CV/dPly/PhtD-10
3+0 
8 excluded 
1 given forbidden vaccine 
1 given forbidden medication 
1 non-compliant blood 
sampling 
5 essential serological data 
missing 
5 excluded 
5 essential serological data 
missing 
10 discontinued treatment 
1 died 
6 withdrew consent 
3 moved away 
200 assigned  
PHiD-CV/dPly/PhtD-30 
3+0 
9 discontinued treatment 
2 died 
1 withdrew consent 
6 moved away 
200 assigned 
PCV13 3+0 
5 excluded 
3 non-compliant blood 
sampling 
2 essential serological data 
missing 
6 discontinued treatment 
1 died 
1 protocol violation 
1 withdrew consent 
3 moved away 
7 excluded 
1 given forbidden vaccine 
1 had forbidden underlying 
medical condition† 
3 non-compliant blood 
sampling 
2 essential serological data 
missing 
200 assigned  
PHiD-CV 2+1 
9 discontinued treatment 
2 died 
3 protocol violation 
2 withdrew consent 
2 moved away 
7 excluded 
3 given forbidden vaccine 
1 non-compliant blood 
sampling 
3 essential serological data 
missing 
200 assigned  
PHiD-CV/dPly/PhtD-30 
2+1 
Fig. 2. Study profile. * Number who were enrolled and underwent study procedure. yConcomitant infection not related to the vaccine which might influence immune
response. ATP, according-to-protocol.
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Table 1
Prevalence of nasopharyngeal carriage of Streptococcus pneumoniae and vaccine efficacy (total vaccinated cohort).
3 + 0 schedule 2 + 1 schedule
PHiD-CV PHiD-CV/dPly/PhtD-10 PHiD-CV/dPly/PhtD-30 PCV13 PHiD-CV PHiD-CV/dPly/PhtD-30
Age at sampling N (95% CI) N (95% CI) VE* (95% CI) N (95% CI) VE* (95% CI) N (95% CI) N (95% CI) N (95% CI) VE* (95% CI)
Any pneumococci
2 M 200 64.5% 200 63.0% 2.3% 200 59.5% 7.8% 200 66.0% 200 67.0% 200 65.0% 3.0%
(57.4, 71.1) (55.9, 69.7) (25.8, 24.2) (52.3, 66.4) (19.3, 28.7) (59.0, 72.5) (60.0, 73.5) (58.0, 71.6) (24.4, 24.4)
5 M 196 84.7% 193 85.5% 0.9% 194 81.4% 3.8% 196 79.1% 197 82.2% 197 80.7% 1.9%
(78.9, 89.4) (79.7, 90.1) (26.0, 19.1) (75.2, 86.7) (20.3, 23.2) (72.7, 84.6) (76.2, 87.3) (74.5, 86.0) (22.9, 21.6)
9 M 194 90.7% 193 86.0% 5.2% 192 83.9% 7.6% 193 87.0% 194 89.2% 189 86.8% 2.7%
(85.7, 94.4) (80.3, 90.6) (17.9, 23.8) (77.9, 88.8) (15.1, 25.8) (81.5, 91.4) (83.9, 93.2) (81.1, 91.3) (21.2, 21.9)
12 M 194 89.7% 189 92.1% 2.6% 189 87.8% 2.1% 191 89.5% 193 91.2% 190 93.7% 2.7%
(84.5, 93.6) (87.2, 95.5) (27.4, 17.3) (82.3, 92.1) (21.8, 21.3) (84.3, 93.5) (86.3, 94.8) (89.2, 96.7) (27.3, 17.1)
5, 9, 12 M visitsy 196 99.5% 194 100% 0.5% 195 100% 0.5% 198 98.5% 198 100% 197 99.0% 1.0%
(97.2, 100) (98.1, 100) (23.2, 18.0) (98.1, 100) (23.2, 18.0) (95.6, 99.7) (98.2, 100) (96.4, 99.9) (21.2, 19.2)
Non-10VT serotypes/groups (primary endpoint)
2 M 200 56.0% 200 58.0% 3.6% 200 55.0% 1.8% 200 60.5% 200 59.0% 200 54.5% 7.6%
(48.8, 63.0) (50.8, 64.9) (35.5, 20.8) (47.8, 62.0) (28.9, 25.2) (53.4, 67.3) (51.8, 65.9) (47.3, 61.5) (20.9, 29.5)
5 M 196 74.0% 193 79.8% 7.9% 194 70.6% 4.5% 196 69.4% 197 77.2% 197 72.1% 6.6%
(67.2, 80.0) (73.4, 85.2) (36.3, 14.6) (63.7, 76.9) (21.4, 25.0) (62.4, 75.8) (70.7, 82.8) (65.3, 78.2) (18.2, 26.2)
9 M 194 82.0% 193 76.7% 6.4% 192 77.6% 5.3% 193 77.7% 194 82.5% 189 77.2% 6.3%
(75.8, 87.1) (70.1, 82.5) (17.8, 25.7) (71.0, 83.3) (19.2, 24.8) (71.2, 83.4) (76.4, 87.5) (70.6, 83.0) (18.0, 25.7)
12 M 194 82.0% 189 79.9% 2.5% 189 81.5% 0.6% 191 81.2% 193 83.9% 190 86.8% 3.5%
(75.8, 87.1) (73.5, 85.4) (22.6, 22.5) (75.2, 86.7) (24.9, 20.9) (74.9, 86.4) (78.0, 88.8) (81.2, 91.3) (29.3, 17.2)
5, 9, 12 M visitsy 196 98.5% 194 97.4% 1.1% 195 96.4% 2.1% 198 97.5% 198 98.0% 197 97.5% 0.5%
(95.6, 99.7) (94.1, 99.2) (21.5, 19.5) (92.7, 98.5) (20.3, 20.3) (94.2, 99.2) (94.9, 99.4) (94.2, 99.2) (22.1, 18.9)
10VT serotypes
2 M 200 10.5% 200 7.0% 33.3% 200 6.5% 38.1% 200 12.5% 200 10.5% 200 13.0% 23.8%
(6.6, 15.6) (3.9, 11.5) (37.5, 68.6) (3.5, 10.9) (29.5, 71.5) (8.3, 17.9) (6.6, 15.6) (8.7, 18.5) (131.4, 33.0)
5 M 196 17.3% 193 12.4% 28.3% 194 16.0% 7.9% 196 14.8% 197 12.2% 197 13.7% 12.5%
(12.3, 23.4) (8.1, 17.9) (24.5, 59.3) (11.1, 21.9) (54.5, 45.2) (10.1, 20.6) (8.0, 17.6) (9.2, 19.3) (103.7, 37.5)
9 M 194 14.4% 193 13.0% 10.3% 192 12.0% 17.0% 193 15.5% 194 11.9% 189 12.7% 7.1%
(9.8, 20.2) (8.6, 18.5) (59.7, 49.8) (7.7, 17.4) (49.4, 54.3) (10.7, 21.4) (7.7, 17.3) (8.3, 18.3) (98.6, 42.1)
12 M 194 8.2% 189 12.7% 54.0% 189 7.9% 3.8% 191 11.0% 193 9.8% 190 9.5% 3.8%
(4.8, 13.0) (8.3, 18.3) (210.2, 21.5) (4.5, 12.8) (107.8, 55.7) (6.9, 16.3) (6.0, 14.9) (5.7, 14.6) (93.7, 52.4)
5, 9, 12 M visitsy 196 32.1% 194 30.4% 5.4% 195 26.7% 17.0% 198 31.3% 198 28.3% 197 27.9% 1.3%
(25.7, 39.2) (24.0, 37.4) (37.1, 34.8) (20.6, 33.5) (21.7, 43.7) (24.9, 38.3) (22.1, 35.1) (21.8, 34.7) (45.8, 33.2)
CI, confidence interval. M, age in months. N, number of infants with cultured nasopharyngeal sample. VE, vaccine efficacy.
* Vaccine efficacy versus corresponding (3 + 0 or 2 + 1 schedule) PHiD-CV group. Vaccine efficacy percentages for the 2 M visit indicate group differences only because the first vaccine dose was administered at this time point.
y Nasopharyngeal carriage prevalence and vaccine efficacy across all post-immunization visits at 5, 9, and 12 months of age.
 10VT corresponds to the 10 vaccine pneumococcal serotypes in PHiD-CV; non-10VT is any serotype/group excluding those in PHiD-CV.
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Table 2
Acquisition of pneumococcal serotypes or serogroups between two consecutive visits (per episode analysis; total vaccinated cohort).
3 + 0 schedule 2 + 1 schedule
PHiD-CV PHiD-CV/dPly/PhtD-10 PHiD-CV/dPly/PhtD-30 PCV13 PHiD-CV PHiD-CV/dPly/PhtD-30
Consecutive sampling ages N (95% CI) N (95% CI) VE* (95% CI) N (95% CI) VE* (95% CI) N (95% CI) N (95% CI) N (95% CI) VE* (95% CI)
Any pneumococci
2 M, 5 M 196 89.8% 193 89.6% 0.2% 194 84.5% 5.9% 196 87.8% 197 89.3% 197 85.8% 4.0%
(77.5, 104.1) (77.2, 104.0) (23.1, 19.1) (72.5, 98.5) (16.5, 23.9) (75.6, 101.9) (77.1, 103.6) (73.8, 99.7) (18.6, 22.2)
5 M, 9 M 194 90.7% 192 79.7% 12.2% 191 78.5% 13.4% 191 90.1% 193 94.8% 189 85.7% 9.6%
(78.3, 105.2) (68.0, 93.4) (9.1, 29.3) (66.9, 92.2) (7.6, 30.4) (77.6, 104.6) (82.0, 109.6) (73.5, 100) (11.7, 26.8)
9 M, 12 M 193 79.3% 189 80.4% 1.4% 189 76.2% 3.9% 190 79.5% 192 73.4% 188 83.5% 13.7%
(67.7, 92.9) (68.6, 94.3) (27.0, 18.9) (64.7, 89.7) (20.7, 23.5) (67.8, 93.2) (62.3, 86.6) (71.4, 97.7) (42.8, 9.4)
Non-10VT serotypes/groupsy
2 M, 5 M 196 74.0% 193 77.2% 4.4% 194 67.0% 9.4% 196 72.4% 197 79.7% 197 72.1% 9.6%
(62.9, 87.1) (65.8, 90.6) (31.2, 17.0) (56.4, 79.6) (14.8, 28.5) (61.5, 85.4) (68.2, 93.2) (61.1, 85.0) (13.5, 27.9)
5 M, 9 M 194 76.3% 192 66.1% 13.3% 191 69.1% 9.4% 191 76.4% 193 81.9% 189 73.5% 10.2%
(64.9, 89.6) (55.6, 78.7) (9.9, 31.6) (58.3, 82.0) (14.5, 28.4) (65.0, 89.9) (70.0, 95.7) (62.3, 86.8) (12.8, 28.5)
9 M, 12 M 193 71.0% 189 70.4% 0.9% 189 67.7% 4.6% 190 69.5% 192 64.1% 188 74.5% 16.2%
(60.0, 83.9) (59.4, 83.4) (25.8, 21.9) (57.0, 80.5) (21.4, 25.0) (58.6, 82.4) (53.7, 76.4) (63.1, 87.9) (48.1, 8.8)
10VT serotypesy
2 M, 5 M 196 13.8% 193 9.8% 28.5% 194 13.9% 1.0% 196 12.8% 197 8.1% 197 11.2% 37.5%
(9.4, 20.1) (6.3, 15.4) (28.5, 60.3) (9.5, 20.3) (72.2, 40.7) (8.6, 18.9) (5.0, 13.3) (7.4, 17.0) (161.8, 27.8)
5 M, 9 M 194 10.8% 192 9.9% 8.6% 191 7.9% 27.4% 191 12.0% 193 10.9% 189 10.1% 7.6%
(7.1, 16.6) (6.3, 15.5) (70.0, 50.8) (4.7, 13.0) (40.7, 62.6) (8.0, 18.1) (7.1, 16.7) (6.4, 15.8) (71.8, 50.3)
9 M, 12 M 193 6.7% 189 9.0% 33.5% 189 6.9% 2.1% 190 8.9% 192 6.8% 188 6.9% 2.1%
(3.9, 11.6) (5.6, 14.5) (174.9, 35.1) (4.0, 11.8) (120.3, 52.7) (5.6, 14.4) (3.9, 11.7) (4.0, 11.9) (120.3, 52.7)
CI, confidence interval. M, age in months. N, number of infants with cultured nasopharyngeal sample. VE, vaccine efficacy.
* Vaccine efficacy versus corresponding (3 + 0 or 2 + 1 schedule) PHiD-CV group.
y 10VT corresponds to the 10 vaccine pneumococcal serotypes in PHiD-CV; non-10VT is any serotype/group excluding those in PHiD-CV.
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Table 3
Clearance of pneumococcal serotypes or serogroups between two consecutive visits (per episode analysis; total vaccinated cohort).
3 + 0 schedule 2 + 1 schedule
PHiD-CV PHiD-CV/dPly/PhtD-10 PHiD-CV/dPly/PhtD-30 PCV13 PHiD-CV PHiD-CV/dPly/PhtD-30
Consecutive sampling ages N (95% CI) N (95% CI) VE* (95% CI) N (95% CI) VE* (95% CI) N (95% CI) N (95% CI) N (95% CI) VE* (95% CI)
Any pneumococci
2 M, 5 M 196 50.5% 193 51.8% 2.6% 194 47.9% 5.1% 196 59.7% 197 54.8% 197 55.3% 0.9%
(41.5, 61.5) (42.6, 63.0) (35.4, 22.3) (39.1, 58.7) (26.0, 28.5) (49.8, 71.6) (45.4, 66.2) (45.9, 66.8) (31.7, 22.7)
5 M, 9 M 194 85.1% 192 85.9% 1.0% 191 85.3% 0.3% 191 88.5% 193 94.8% 189 85.2% 10.2%
(73.0, 99.1) (73.8, 100.1) (25.4, 18.6) (73.2, 99.5) (24.6, 19.2) (76.1, 102.9) (82.0, 109.6) (73.0, 99.4) (11.0, 27.3)
9 M, 12 M 193 91.2% 189 84.1% 7.7% 189 73.5% 19.4% 190 86.8% 192 80.7% 188 81.4% 0.8%
(78.7, 105.7) (72.0, 98.3) (14.3, 25.6) (62.3, 86.8) (0.7, 35.4) (74.6, 101.2) (69.0, 94.5) (69.5, 95.4) (26.0, 19.4)
Non-10VT serotypes/groupsy
2 M, 5 M 196 41.3% 193 47.2% 14.1% 194 41.8% 1.0% 196 46.9% 197 47.2% 197 41.6% 11.8%
(33.2, 51.4) (38.4, 57.9) (53.9, 15.4) (33.6, 51.9) (37.5, 25.7) (38.3, 57.6) (38.5, 57.8) (33.5, 51.7) (18.7, 34.5)
5 M, 9 M 194 69.6% 192 75.0% 7.8% 191 69.1% 0.7% 191 74.9% 193 82.4% 189 72.0% 12.7%
(58.8, 82.4) (63.7, 88.3) (36.3, 14.8) (58.3, 82.0) (26.2, 21.9) (63.6, 88.2) (70.5, 96.2) (60.8, 85.1) (9.8, 30.5)
9 M, 12 M 193 74.1% 189 71.4% 3.6% 189 60.3% 18.6% 190 72.1% 192 70.8% 188 69.7% 1.6%
(62.9, 87.3) (60.3, 84.6) (22.0, 23.8) (50.2, 72.5) (4.1, 36.4) (61.0, 85.2) (59.9, 83.8) (58.7, 82.7) (25.0, 22.6)
10VT serotypesy
2 M, 5 M 196 7.1% 193 4.7% 34.7% 194 4.6% 35.1% 196 10.7% 197 7.1% 197 10.7% 50.0%
(4.2, 12.1) (2.4, 9.0) (50.8, 71.7) (2.4, 8.9) (50.1, 71.9) (7.0, 16.4) (4.2, 12.0) (7.0, 16.3) (195.0, 23.7)
5 M, 9 M 194 13.4% 192 9.4% 30.0% 191 12.0% 10.1% 191 11.0% 193 10.9% 189 10.6% 2.7%
(9.1, 19.7) (5.9, 14.9) (27.6, 61.6) (8.0, 18.1) (57.5, 48.7) (7.2, 16.9) (7.1, 16.7) (6.8, 16.4) (79.4, 47.3)
9 M, 12 M 193 12.4% 189 10.1% 19.2% 189 11.1% 10.6% 190 13.2% 192 8.3% 188 10.1% 21.3%
(8.3, 18.6) (6.4, 15.8) (47.6, 55.7) (7.2, 17.0) (60.5, 50.3) (8.9, 19.5) (5.1, 13.6) (6.4, 15.8) (135.8, 37.6)
CI, confidence interval. M, age in months. N, number of infants with cultured nasopharyngeal sample. VE, vaccine efficacy.
* Vaccine efficacy versus corresponding (3 + 0 or 2 + 1 schedule) PHiD-CV group; negative vaccine efficacy indicates more clearance in PHiD-CV/dPly/PhtD group than in PHiD-CV group.
y 10VT corresponds to the 10 vaccine pneumococcal serotypes in PHiD-CV; non-10VT is any serotype/group excluding those in PHiD-CV.
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Fig. 3. Reverse cumulative distribution curves for pneumococcal bacterial load in nasopharyngeal swabs at 2 (A), 5 (B), 9 (C), and 12 (D) months of age at sampling (total
vaccinated cohort for quantitative PCR analysis). N, maximum number of infants with available results at each time point; copies/mL, gene copies per mL. The dotted line
indicates the lower limit of detection (cut-off: 1000 copies/mL).
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Fig. 4. Antibody geometric mean concentrations with 95% confidence intervals against Ply (A) and PhtD (B) by age at sampling (according-to-protocol cohort for
immunogenicity). CI, confidence interval; GMC, geometric mean concentration; N, maximum number of infants with available results at each time point; EL.U/mL, ELISA units
per mL.
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concentrations against Ply from pre-vaccination to last post-
vaccination time point in PHiD-CV/dPly/PhtD groups compared
with no, or slight, increase in control PHiD-CV or PCV13 groups
(Fig. 4). The magnitude of increased antibody responses to PhtD
was smaller (a 2.3–4.0-fold increase in PHiD-CV/dPly/PhtD groups
versus a 1.9–2.8-fold increase in control PHiD-CV or PCV13 groups)
(Fig. 4). In the control groups, Ply and PhtD antibody GMCs
dropped by 42–62% between pre-vaccination and age of 5 months,
while antibody GMCs increased in the PHiD-CV/dPly/PhtD groups.
For the 3 + 0 schedule, the confirmatory objective on dose superi-
ority was not met as the 95% CI for the GMC ratio for antibody
responses against both Ply and PhtD after the third vaccine dose
did not exclude 1 (Supplementary Table S7). For antibody
responses against Ply, the adjusted GMC was higher for the 30 lg
than the 10 lg dose while for anti-PhtD responses, the trend was
the reverse.
No differences in IgG antibody response against Ply or PhtD
were observed in subsets of infants with or without pneumococcal
NPC before vaccination (Supplementary Fig. S2).
3.4. Gene sequencing
Among 350 selected NPC isolates containing non-10VT
serotypes/groups, 347 were positive for ply and 342 were positive
for phtD genes. Sequencing results are provided in Supplementary
Text 3 and Tables S8–11. Briefly, 18 Ply protein variants were
obtained, with variant 1 (100% identity with Ply used for PHiD-
CV/dPly/PhtD vaccine) being the most common and present in
62% of samples positive for ply. High sequence identity (at least
98.5%) was observed, corresponding to a maximum of seven amino
acid substitutions among all Ply protein variants. For PhtD, 84 pro-
tein sequences were detected, with no clear major variant. All PhtD
variants except four (but including the variant used for PHiD-CV/
dPly/PhtD vaccines) showed 91.8–99.9% protein identity. Compar-
ison of protein-based vaccine and control PHiD-CV groups showed
PHiD-CV/dPly/PhtD vaccination had no impact on the prevalence
of Ply variant 1. There was also no evidence of an impact on aver-
age Ply or PhtD sequence identity relative to the amino acid
sequences of the proteins in the vaccine.
3.5. Reactogenicity and safety
Incidences of solicited and unsolicited adverse events (AEs)
were comparable among groups (Supplementary Tables S12 and
S13). Reports of pain at the PHiD-CV/dPly/PhtD vaccine injection
site tended to be less frequent than reported for co-administered
vaccines (Supplementary Fig. S3). There were few reports of related
or grade 3 unsolicited AEs (Supplementary Table S13). A total of 21
serious AEs (SAEs) were reported for 19 infants, none of which was
assessed by the investigator as causally related to vaccination. Six
SAEs were fatal (Supplementary Text 4), three in the investiga-
tional arms and three in the control groups, with diagnoses of aspi-
ration pneumonia for one case in the PHiD-CV/dPly/PhtD-30 (3 + 0
schedule) group, acute gastroenteritis and sudden infant death
syndrome for one case each in the PHiD-CV/dPly/PhtD-30 (2 + 1)
group, gastroenteritis for one case in the PHiD-CV (2 + 1) group,
and bronchopneumonia and sepsis for one case each in the
PCV13 group.
4. Discussion
We evaluated the impact of two formulations of an investiga-
tional vaccine containing two pneumococcal proteins combined
with polysaccharide conjugates of the 10-valent PHiD-CV (PHiD-
CV/dPly/PhtD) on NPC prevalence and their immunogenicity and
safety in infants. The study was carried out in a community in
The Gambia where the prevalence of pneumococcal carriage
among infants was known to be very high [24]. In this trial setting,
we did not show that addition of the pneumococcal proteins dPly
and PhtD reduces the prevalence of non-10VT carriage beyond that
provided by PHiD-CV, the primary trial endpoint. We found that
the prevalence of pneumococcal carriage, acquisition or clearance
of carriage, and pneumococcal load as detected by qPCR and cul-
ture were similar across study groups. The trial was well powered
to detect a statistical difference of 25% between each of the PHiD-
CV/dPly/PhtD groups and the PHiD-CV control groups, given the
incidence of non-10VT carriage observed in the study. Protein dose
superiority (10 or 30 lg) in terms of immunogenicity for both pro-
teins was not demonstrated. Gene sequencing results did not sug-
gest that the lack of impact on carriage was due to an absence of
ply or phtD genes in S. pneumoniae strains colonizing infants in
The Gambia or divergence in Ply or PhtD protein sequences. Also,
exploratory analyses showed baseline carriage status of infants
and the time of year when infants presented for first vaccination
had no clear effects on efficacy against NPC prevalence of non-
10VT or any pneumococci.
Despite the fact that all infants had background antibodies to both
proteins before vaccination, robust antibody responses to the Ply
component were seen, resulting in substantially higher antibody
levels in dPly-containing vaccine recipients compared to control
and this difference was sustained up to the age of 12 months. For
PhtD, the magnitude of the antibody response versus control was
greatest at 5 months, with diminishing differences between groups
at 9 and 12months. The fold increase in antibody concentration from
pre- to post-vaccination was lower for PhtD than for Ply in all groups.
Anti-Ply GMCs were higher in infants who received the 30 lg vaccine
formulation than in those who received the 10 lg formulation,
whereas the reverse trend was observed for anti-PhtD concentra-
tions. This differs from findings in European infants, where superior-
ity with the 30 lg dose was demonstrated for both proteins one
month after three-dose PHiD-CV/dPly/PhtD priming [25]. In the con-
trol groups, antibody GMCs against Ply and PhtD decreased between
pre-vaccination and 5months of age, which is attributed to waning
maternal antibodies [26,27].
To our knowledge, this was the first study designed and pow-
ered to evaluate the effect of pneumococcal proteins against bacte-
rial carriage in infants as the primary endpoint. There are few
reports from other studies that have investigated the impact of
protein-based vaccines against pneumococcal NPC prevalence in
humans. A study of a trivalent recombinant protein pneumococcal
vaccine containing PhtD, PlyD1 (a genetically detoxified Ply), and
pneumococcal choline-binding protein A (PcpA) conducted in Ban-
gladesh examined impact on carriage but not as a primary or sec-
ondary outcome measure [10]. Initial reports from this study
suggested there was no significant difference in carriage preva-
lence of pneumococci between vaccinated and control groups
[28]. First results are also available from an experimental pneumo-
coccal challenge study of 96 adults in the UK with a protein-based
vaccine containing three T-cell antigens, SP0148, SP1912, and
SP2108 [14]. At sampling points up to 14 days after inoculation,
pneumococcal NPC prevalence was reduced by 18–36% versus pla-
cebo but the group differences were not statistically significant.
In pre-clinical studies, Ply and PhtD, administered either sepa-
rately or in combination, showed protection against lethal chal-
lenge and pneumococcal disease [17–23,29] and were therefore
considered for vaccine development to provide broader protection
against pneumococcal disease. They also showed protection
against pneumococcal NPC prevalence [22,23,30]. In studies con-
ducted by our group, protection against NPC was observed in mice
after immunization with dPly and PhtD only when the proteins
were administered via an intranasal route and using Escherichia coli
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labile toxin as adjuvant [22,23]; there was no protection when the
proteins were administered systemically (unpublished data),
which is consistent with the results of the present clinical study.
In contrast, another study reported protection against pneumococ-
cal NPC in mice administered with anti-Ply and anti-PhtD antibod-
ies intravenously [30]. Therefore, although pre-clinical
assessments suggest that immunization with dPly and PhtD anti-
gens may play a role in protection against NPC, this effect may
depend on the route of administration of the antigens.
It is possible that the characteristics of the induced immune
response leading to an impact on carriage in animals differ from
those induced in the clinical study. As well as the difference in
immunization route, this may be due to differences in the adjuvant
and/or initial immune status of mice versus Gambian infants. In
the pre-clinical studies conducted by our group, E. coli labile toxin
was used as adjuvant [22,23], while aluminum phosphate was
used in the clinical study. Immune responses may vary with differ-
ent adjuvants, particularly stronger induction of T-cell responses,
which is thought to be involved in protection against NPC [31],
but this was not assessed in this study.
Moreover, the clinical study was conducted in a setting where
the prevalence of pneumococcal NPC among infants is high (pneu-
mococcal and non-10VT NPC prevalence at baseline were 60–67%
and 55–61%, respectively) and therefore most, if not all, infants
would have been immunologically primed by prior or ongoing car-
riage events. Thus intramuscular immunization of Gambian infants
might have boosted a mucosal immune response primed by natu-
ral NP exposure. This was contrary to the initial unexposed and
therefore immunologically naïve status of animals in the pre-
clinical studies.
The trial was well conducted with a very high completion rate
and detailed evaluation of the impact of the vaccine including mea-
surement of bacterial acquisition, clearance, and load. The method-
ology developed will be of interest to other groups contemplating
pneumococcal vaccine trials with NPC as an endpoint. However,
our study had some limitations. Intervals between sampling time
points were relatively long and consequently the sensitivity of
tests for acquisition or clearance of carriage was probably not opti-
mal. Another limitation was that the study was not powered to
detect a smaller reduction (below 25%) in non-10VT carriage due
to the initial assumption of higher vaccine efficacy against this
endpoint. Reduction of carriage by less than 25% might not pre-
clude efficacy on disease since a dynamic model of pneumococcal
infection predicted that 20% effectiveness with PCV7 against vac-
cine serotype carriage would have a major impact on IPD caused
by these serotypes [32]. No observed effect on carriage prevalence
also does not preclude an effect on host-to-host transmission as
other mechanisms such as reduction of local inflammation might
be involved [33], but this was not evaluated in this study. We also
did not investigate T-cell responses to the investigational vaccine,
which might have enabled us to better understand the nature of
the immune response to the pneumococcal proteins.
In conclusion, our study showed that inclusion of pneumococcal
proteins in the PHiD-CV/dPly/PhtD investigational vaccine had no
impact on pneumococcal NPC prevalence in infants, regardless of
protein dose or schedule. However, the quantitative relationship
between the pneumococcal protein-containing vaccines’ impact
on NPC prevalence and its impact on pneumococcal disease in
humans is yet to be defined, and no effect on carriage does not pre-
clude protection against disease. Another infant trial (ClinicalTri-
als.gov, NCT01545375) is evaluating protection against acute
otitis media in infants receiving dPly and PhtD antigens. If the pro-
tein antigens are proven effective in disease protection, their use in
combination with conjugates could add value by extending protec-
tion to a larger set of pneumococcal serotypes while maintaining
the well established effect of the existing PCV.
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